MedTrace Logo

Study of Leukocyte Interleukin, Injection for Treatment of Perianal Warts

NCT03038828 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2023-09-22

No results posted yet for this study

Summary

Study is a dose escalation study. Fifteen patients will be enrolled in 2 treatment cohorts. Five participants (cohort A) will be treated with 200IU Multikine daily, 5 days/week for 2 weeks, off 2 weeks, then again 5 days/week for 2 weeks. If no serious adverse events are noted in cohort A patients, ten participants will be treated in cohort B. Cohort B participants will be treated the same as cohort A participants except that dose will be increased to 400IU Multikine per day.

Conditions

  • Perianal Warts

Interventions

BIOLOGICAL

Leukocyte Interleukin, Injection

Immunotherapy

Sponsors & Collaborators

  • Ergomed Clinical Research Inc.

    collaborator UNKNOWN

  • United States Naval Medical Center, San Diego

    collaborator FED

  • CEL-SCI Corporation

    lead INDUSTRY

Principal Investigators

  • Eyal Talor, PhD · CEL-SCI Chief Scientific Officer

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2018-06-30
Completion
2018-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03038828 on ClinicalTrials.gov